December 1st, 2014
Selections from Richard Lehman’s Literature Review: December 1st
Richard Lehman, BM, BCh, MRCGP
This week’s topics include atenolol vs. losartan in children and young adults with Marfan’s syndrome, the Japanese Primary Prevention Project, and more.
November 3rd, 2014
Economic Study Finds VTE Prophylaxis with Low-Molecular-Weight Heparin Cost Effective
Larry Husten, PHD
Critically ill patients in the hospital are at high risk for developing venous thromboembolism (VTE). The 2011 PROTECT trial compared the two most common drug strategies used to prevent VTE — unfractionated heparin (UFH) and dalteparin, a low-molecular-weight heparin (LMWH) — and found no difference between the two groups in the primary endpoint of the trial, leg deep-vein thrombosis. But […]
March 22nd, 2011
PROTECT Compares Unfractionated Heparin And Dalteparin In Critically Ill Patients
Larry Husten, PHD
ICU patients are at high risk to develop venous thromboembolism. Published in NEJM, PROTECT (the Prophylaxis for Thromboembolism in Critical Care Trial) compared the effects of the low-molecular-weight heparin dalteparin with unfractionated heparin (UFH) in 3746 critically ill patients. There was no significant difference between the two groups in the primary outcome of the trial. Proximal […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?